Monday, July 24, 2017

Netherlands-based AI company moves toward lung cancer prediction

PARCA eNews – July 1, 2017 – Amsterdam-based Aidence expects its first CE marking for the European market in the third quarter of this year, according to a press release.
The company, which is developing AI technology for imaging diagnostics, recently raised 2.25 million from a group of investors that includes HenQ, Health Innovations, Northzone,  and physicians from the Hague-based Haaglanden hospital group.

The company says it is currently working to adapt its software to identify other pathologies on chest CT as well as MR imaging of joints and the brain. It also plans applications for triage and workflow optimization, screening programs and routine clinical practice.
“Our ultimate goal is to reach a level of diagnostic accuracy that matches the collective knowledge of all human experts—and then bring it to every hospital in the world,” says CEO Mark-Jan Harte.
Earlier this year, Aidence took third place in the 2017 Kaggle Data Science Bowl, a $1 million global contest to build software to predict lung cancer based on a single chest CT scan.
Source: HealthImaging

No comments:

Post a Comment